- Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians ...
- Ortho receives FDA Emergency Use Authorization for its second COVID-19 antibody test - Similar to Ortho's total COVID-19 antibody test, Ortho's IgG test demonstrated 100% specificity and can be used ...
- Ortho's new SARS-CoV-2 antigen test offers 98.9% concordance[i] to real-time PCR tests, making it a viable alternative suitable for mass-scale testing - Ortho's new SARS-CoV-2 antigen test is the ...
RARITAN, N.J., April 13, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for ...
– The new contract will deliver Ortho with funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market over the next 12-14 months “Ortho’s ...
- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of ...
- Ortho's VITROS® SARS-CoV-2 antigen test can detect SARS-CoV-2 infection in asymptomatic individuals. - The low-cost VITROS antigen test can run up to 130 tests per hour and is a viable choice for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results